RCM
GILD icon

Radnor Capital Management’s Gilead Sciences GILD Stock Holding History

Radnor Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,733
Closed -$229K – 320
2024
Q3 		$229K Buy
+2,733
New +$209K 0.03% 313
2023
Q2 		– Sell
-2,440
Closed -$202K – 172
2023
Q1 		$202K Hold
2,440
– – 0.05% 205
2022
Q4 		$217K Buy
+2,440
New +$193K 0.05% 227

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Radnor Capital Management's GILD Position: Q4 2024 in Review

Radnor Capital Management sold out of Gilead Sciences (GILD) in Q4 2024, closing a stake of 2,733 shares — an estimated $229K sold.

Radnor Capital Management first reported a position in GILD in Q4 2022 and held it in 3 quarters. The position peaked at $229K in Q3 2024. 1,887 funds tracked by Wall St. Rank hold GILD as of Q4 2024.

  • Radnor Capital Management reported no remaining Gilead Sciences position as of Q4 2024 after selling out during the quarter.
  • Radnor Capital Management sold 2,733 Gilead Sciences shares in Q4 2024, an estimated $229K.
  • Radnor Capital Management first reported a position in Gilead Sciences in Q4 2022 and held it in 3 quarters.
  • Radnor Capital Management's Gilead Sciences position peaked at $229K in Q3 2024.
  • 1,887 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2024.

Based on Radnor Capital Management's 13F filing for Q4 2024, filed 14 Jan 2025.